首 页   本刊简介  编委会  审稿专家  在线期刊  写作规范  广告合作  联系我们
您现在的位置:首页 => 在线期刊 => 7期肝癌的诊断和治疗 => 综述 =>利福昔明在肝硬化相关并发症中的应用
利福昔明在肝硬化相关并发症中的应用
Clinical effect of rifaximin in treatment of complications associated with liver cirrhosis
文章发布日期:2018年06月07日  来源:  作者:吕新月,李磊  点击次数:67次  下载次数:12次

调整字体大小:

(此处下载失败可以在在线预览处保存副本或者右键另存为)

【摘要】:肝硬化患者往往死于其并发症,其中肝性脑病是肝硬化最常见的死亡原因,而上消化道出血为肝硬化最常见的并发症。近年来随着肝硬化肠道菌群及炎症反应的相关研究的不断进展,一种肠道选择性的口服抗菌药物利福昔明在肝硬化患者中的应用引起了国内外的普遍关注。分析了近年来利福昔明在肝硬化相关并发症中应用的研究,以期对该方向的后续研究及临床实践提供一些合理性的建议。
【Abstract】:Patients with liver cirrhosis often die of complications, among which hepatic encephalopathy is the primary cause of death and upper gastrointestinal bleeding is the most common complication of liver cirrhosis. In recent years, with the continuous progress in the research on intestinal flora and inflammatory response in patients with liver cirrhosis, rifaximin, a selective oral antibacterial agent, has attracted more and more attention in China and foreign countries. This article analyzes the studies on rifaximin in the treatment of complications associated with liver cirrhosis, in order to provide reasonable suggestions for subsequent studies and clinical practice.
【关键字】:利福昔明;肝硬化;肝性脑病;综述
【Key words】:rifaximin; liver cirrhosis; hepatic encephalopathy; review
【引证本文】:LYU XY, LI L. Clinical effect of rifaximin in treatment of complications associated with liver cirrhosis[J]. J Clin Hepatol, 2018, 34(7): 1551-1554. (in Chinese)
吕新月, 李磊. 利福昔明在肝硬化相关并发症中的临床应用[J]. 临床肝胆病杂志, 2018, 34(7): 1551-1554.

地址:长春市东民主大街519号《临床肝胆病杂志》编辑部 邮编:130061 电话:0431-88782542/3542
临床肝胆病杂志 版权所有 Copyright © 2009 - 2013 Lcgdbzz.org. All Rights Reserv 吉ICP备10000617号

吉公网安备 22010402000041号